Corporate Governance
How is our business structured and managed?
We have a clear structure in which the Board reserves and delegates its powers
David Brennan
Executive Director and Chief Executive Officer (Age 57)
Appointed as a Director in March 2005 and as CEO in January 2006. David Brennan is President of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) and a member of the executive board of the European Federation of Pharmaceutical Industries and Associations (EFPIA). He is a past Chairman of the board of the Pharmaceutical Research and Manufacturers of America (PhRMA) and remains a member of the PhRMA board. From 2001 until January 2006, he was President and Chief Executive Officer of the Company’s North American subsidiary. He was Chairman of the board of the Southeastern Pennsylvania Chapter of the American Heart Association 2004- 2006. He began his career in 1975 at Merck, where he started as a sales representative in the US division and later worked in sales and marketing management in the US and international divisions. He joined Astra Merck in 1992 and helped to build the joint venture into a multi-billion dollar business in the US. He is an alumnus of Gettysburg College where he studied Business Administration.
Simon Lowth
Executive Director and Chief Financial Officer
Appointed as a Director and as CFO in November 2007. Simon Lowth is also a Non-Executive Director of Standard Chartered PLC. He was previously at ScottishPower where he was Finance Director, a position he left following completion of the sale of the company to Iberdrola. His move to ScottishPower followed 15 years’ experience with the global management consultancy, McKinsey & Company, where he advised leading multinational companies on a wide range of strategic, financial and operational issues. He has an engineering degree from Cambridge University and an MBA from the London Business School.
Martin Mackay
President, Global R&D
Martin Mackay joined AstraZeneca in July. He was previously at Pfizer Inc. where he was Head of PharmaTherapeutics R&D and a member of the Pfizer Inc. executive leadership team. Prior to joining Pfizer Inc. in 1995, he held several discovery and development roles culminating in his appointment as Head of Molecular and Cell Biology, CNS Research at Ciba-Geigy. He has a degree in microbiology from Heriot-Watt University and a PhD in molecular genetics from the University of Edinburgh.
Jeff Pott
General Counsel
Jeff Pott was appointed General Counsel in January 2009 and has overall responsibility for all aspects of AstraZeneca’s Legal and Intellectual Property function. He joined AstraZeneca in 1995 and has worked in various litigation roles, where he has had responsibility for intellectual property, anti-trust and product liability litigation. Prior to joining AstraZeneca, he spent five years at the US legal firm Drinker Biddle and Reath LLP, where he specialised in pharmaceutical product liability litigation and anti-trust advice and litigation. He received his bachelor’s degree in political science from Wheaton College and his Juris Doctor Degree from Villanova University School of Law.
David Smith
Executive Vice-President, Global Operations and Information Services
David Smith joined AstraZeneca in 2006 as Executive Vice-President, Operations. He leads AstraZeneca’s global manufacturing and supply organisation and is also responsible for the Safety, Health and Environment; Regulatory Compliance; Procurement; and Engineering functions and has overall responsibility for Information Services. He spent his early career in pharmaceuticals, initially with the Wellcome Foundation in the UK. He subsequently spent nine years in the consumer goods sector working for Estée Lauder and Timberland in senior supply chain roles. In 2003, he returned to the pharmaceutical sector and joined Novartis in Switzerland.
Lynn Tetrault
Executive Vice-President, Human Resources and Corporate Affairs
Lynn Tetrault was appointed Executive Vice-President, Human Resources and Corporate Affairs in 2007, having previously been Vice-President, Corporate Affairs. She has also held the role of Vice-President HR, Global Drug Development and Vice-President, HR for the US subsidiary of AstraZeneca following the merger between Astra and Zeneca. She started her career in private law practice where she specialised in general corporate and healthcare law. She joined Astra USA in 1993 as Associate General Counsel in the company’s legal department. She received her bachelor’s degree from Princeton University and her law degree from the University of Virginia Law School.
Tony Zook
Executive Vice-President, Global Commercial Operations
Tony Zook was appointed Executive Vice-President of AstraZeneca’s global Commercial organisation in January 2010. He has responsibility for worldwide sales and marketing activities, as well as the commercial infrastructure in support of those efforts. Prior to his current role, he was President and CEO for AstraZeneca’s US business and headed AstraZeneca’s Global Marketing function. He was also President of MedImmune. He has held various other positions in AstraZeneca’s sales and marketing organisation. He joined Astra USA in 1997 as Vice-President, Marketing and Sales, having begun his pharmaceutical career at Berlex Laboratories. He earned a bachelor’s degree in biology from Frostburg University and an associate’s degree in chemical engineering from Pennsylvania State University. He is a member of the board for First State Innovation, the Pennsylvania Division of the American Cancer Society and is a member of the Board of Trustees for the Healthcare Leadership Council.